Prognostic Parameters of Metastatic Adrenocortical Carcinoma
Open Access
- 1 January 2007
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (1), 148-154
- https://doi.org/10.1210/jc.2006-0706
Abstract
Context: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized. Objective: The objective of the study was to describe the clinical presentation of metastatic ACC and determine prognostic factors for survival. Design: This was a retrospective cohort study (1988–2004). Setting: The study was conducted in an institutional practice. Patients: Participants included 124 consecutive patients with metastatic ACC, 70 from Gustave-Roussy Institute (main cohort) and 54 patients from the Cochin Hospital (validation cohort). Clinical data concerning all patients, histopathologic slides of primary tumors (44 in the main cohort and 40 in the validation cohort), and molecular biology data on 15 primary tumors (main cohort) were analyzed. Intervention: There was no intervention. Main Outcome: The main outcome was the specific survival after discovery of the first metastasis (Kaplan-Meier method). This included univariate analysis on the main cohort, confirmed on the validation cohort and then analyzed in a multivariate analysis. Results: In the main cohort, overall median survival was 20 months. In univariate analysis, the presence of hepatic and bone metastases, the number of metastatic lesions and the number of tumoral organs at the time of the first metastasis, a high mitotic rate (>20 per 50 high-power field), and atypical mitoses in the primary tumor predicted survival (P = 0.05, 0.003, 0.046, 0.001, 0.01, and < 0.001, respectively). The number of tumoral organs and a high mitotic rate were confirmed on the validation cohort (P = 0.009 and 0.03, respectively). These two parameters were confirmed in multivariate analysis (P = 0.0058 and 0.049). Conclusion: Metastatic ACC is a heterogeneous disease with poor outcome. The combination of the number of tumoral organs at the time of the first metastasis and the mitotic rate can predict different outcomes.Keywords
This publication has 37 references indexed in Scilit:
- Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular CharacterizationJournal of Clinical Oncology, 2002
- Adrenocortical carcinomaCancer, 2001
- Adrenocortical carcinomas: surgical trends and results of a 253‐patient series from the French Association of Endocrine Surgeons study groupWorld Journal of Surgery, 2001
- Adrenocortical Carcinoma: Is Prognosis Different in Nonfunctioning Tumors? Results of Surgical Treatment in 31 PatientsWorld Journal of Surgery, 2001
- Adrenocortical CarcinomaArchives of Surgery, 2001
- Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical CarcinomaAnnals of Surgical Oncology, 1999
- Adrenocortical Carcinoma: Experience in 45 PatientsOncology, 1997
- The Italian registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patientsSurgery, 1996
- Adrenal cortical carcinoma in Norway, 1970–1984World Journal of Surgery, 1992
- Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane TherapyNew England Journal of Medicine, 1990